Secukinumab and infectious adverse effects: A real‐life experience of 63 psoriasis patients

Ergun, Tülin; Seçkin, Dilek; Demir, Gizem; Direşkeneli, Haner

doi:10.1111/ajd.13588

Cited by 6 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KEGG pathways of infectious diseases: parasitic and viral were significantly increased after secukinumab therapy in psoriasis. Actually, infection is the most reported side effect of secukinumab therapy, which is in accordance with our data on gut microbiota (Ergun et al, 2021 ). It should be given more attention when using secukinumab treatment.…”

Section: Discussionsupporting

confidence: 92%

Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes

Du,

Yan,

Kong

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

IntroductionThe role of gut microbiome dysbiosis in the pathogenesis of psoriasis has gained increasing attention in recent years. Secukinumab, targeting interleukin (IL)-17, has a promising efficacy in psoriasis treatment. However, it remains unclear the gut microbiota alteration and related functional changes caused by successful secukinumab therapy in psoriatic patients.MethodsIn our study, we compared the fecal microbiome profile between psoriatic patients after secukinumab successful treatment (AT) and the other two groups, psoriatic patients without therapy (BT) and healthy people (H), respectively, by using next-generation sequencing targeting 16S ribosomal RNA. Then, shotgun metagenomic sequencing was first used to characterize bacterial gut microbial communities and related functional changes in the AT group.ResultsWe found that the diversity and structure of the microbial community in the AT group were significantly changed compared to those in the BT group and the H group. The AT group showed a microbiota profile characterized by increased proportions of the phylum Firmicute, families Ruminococcaceae, and a reduction in the phylum Bacteroidota (elevated F/B ratio). To detect functional alteration, we discovered that secukinumab treatment may construct a more stable homeostasis of the gut microbiome with functional alteration. There were different KEGG pathways, such as the downregulated cardiovascular diseases pathway and the upregulated infectious diseases in the AT group. By metagenomic analysis, the metabolic functional pathway was changed after secukinumab therapy.DiscussionIt seems that gut microbiota investigation during biologic drug treatment is useful for predicting the efficacy and risks of drug treatment in disease.

show abstract

Section: Discussionsupporting

confidence: 92%

Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes

Du,

Yan,

Kong

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…On the contrary, KEGG pathways of infectious diseases: parasitic and viral were signi cantly increased after secukinumab therapy in psoriasis. Actually, infection is the most reported side effect of secukinumab therapy, which is in accordance with our data in gut microbiota [32]. And it should be given more attention when using secukinumab treatment.…”

Section: Discussionsupporting

confidence: 89%

Successful treatment of psoriasis with secukinumab constructed a new homeostasis of gut microbiome

Yan

Kong

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Secukinumab (an interleukin (IL)-17 inhibitor) has been reported to be able to alter gut microbiome composition in psoriatic patients. However, it still remains unclear the gut microbiota alteration and related functional changes caused by successful secukinumab therapy in psoriatic patients. In this study, fecal samples from healthy people as comtrol (H; n=35), psoriatic patients without therapy (BT; n=32) and patients after 5-month successful secukinumab treatment (AT; n=11) were collected., Then gut microbiomes were investigated using next-generation sequencing targeting 16S ribosomal RNA. Results: Successful secukinumab therapy caused a significantly elevated microbiota richness and biodiversity, as well as an alteration in the gut microbiota composition than psoriasis without therapy and healthy control. The psoriatic patients after secukinumab successful therapy showed a microbiota profile characterized by increased proportions of the phylum Firmicute, families Comamonadaceae and Erwiniaceae, and a reduction in the phylum Bacteroidota, compared to the other two groups. Besides, we discovered that secukinumab treatment group exhibited more significant abundance in contains mobile elements phenotype, form biofilms phenotype, gram positive phenotype, and less abundance in gram negative phenotype and potentially pathogenic phenotype by BugBase. Functional analysis showed the different COG pathways and KEGG pathways such as downregulated cardiovascular diseases pathway and upregulated infectious diseases between secukinumab therapy group and the other two groups.Conclusions: Secukinumab therapy enhanced the diversity of gut microbiota and altered the composition of the gut microbiome, which actually may construct a more stable homeostasis of gut microbiome with less potentially pathogenicity.

show abstract

“…There has been a similar report of NTM infection of the cubital fossa in an elderly patient with history of topical corticosteroid application. 4 Finally, we emphasise the emergence of Mycobacterium abscessus, with its multi-drug resistance pattern 5 and potential need for intravenous therapy or surgical intervention. Although Mycobacterium abscessus is a fast growing mycobacterium, cultures had a turnaround time of 4-6 weeks in our cases, longer than the traditionally understood timing of 2 weeks.…”

mentioning

confidence: 99%

Cutaneous non‐tuberculous mycobacterial infection in Singapore: The ‘cubital forearm’ sign‐ a complication of topical corticosteroid use

Tay¹,

Yang²,

Tan

et al. 2021

Aust J Dermatology

View full text Add to dashboard Cite

show abstract

Secukinumab and infectious adverse effects: A real‐life experience of 63 psoriasis patients

Cited by 6 publications

References 12 publications

Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes

Successful secukinumab therapy in plaque psoriasis is associated with altered gut microbiota and related functional changes

Successful treatment of psoriasis with secukinumab constructed a new homeostasis of gut microbiome

Cutaneous non‐tuberculous mycobacterial infection in Singapore: The ‘cubital forearm’ sign‐ a complication of topical corticosteroid use

Contact Info

Product

Resources

About